Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GlaxoSmithKline was formerly called GlaxoWelcome ... You can also buy U.K. stocks directly on the London Stock Exchange with an Interactive Brokers or Charles Schwab International brokerage ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK bought into the EOS-448 programme last year in a deal orchestrated by its chief scientific officer Hal Barron, who is leaving to join biotech startup Altos at the beginning of August.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...